Gülkaş Samet, Şahin Özlem
Şanlıurfa Training and Research Hospital, Ophthalmology Clinic, Şanlıurfa, Turkey
Marmara University Faculty of Medicine, Department of Ophthalmology, İstanbul, Turkey
Turk J Ophthalmol. 2019 Feb 28;49(1):30-39. doi: 10.4274/tjo.galenos.2018.49035.
Central serous chorioretinopathy (CSCR) is the second most common maculopathy after diabetic maculopathy between the third and fifth decades of life. CSCR is characterized by serous neurosensory retinal detachment occasionally coexisting with retinal pigment epithelium (RPE) detachment. CSCR usually has good clinical prognosis, often resolving spontaneously within the first three months. However, some patients may have recurrent episodes and chronic disease. CSCR can cause permanent visual loss due to persistent neurosensory retinal detachment and RPE atrophy, especially in chronic cases. In recent years, verteporfin-photodynamic therapy applied with standard and low-dose/low-fluence protocols, anti-vascular endothelial growth factors, glucocorticoid antagonists, mineralocorticoid receptor antagonists, and subthreshold micropulse laser with varying parameters have been investigated as treatment options. In this review, we evaluated randomized and non-randomized case series conducted after 2000 that included at least 3 patients with chronic CSCR over 3 months in duration who were treated with current treatment options for chronic CSCR.
中心性浆液性脉络膜视网膜病变（CSCR）是30至50岁人群中仅次于糖尿病性黄斑病变的第二常见黄斑病变。CSCR的特征是浆液性神经感觉视网膜脱离，偶尔与视网膜色素上皮（RPE）脱离并存。CSCR通常具有良好的临床预后，常在头三个月内自发消退。然而，一些患者可能会复发并发展为慢性病。CSCR可因持续性神经感觉视网膜脱离和RPE萎缩导致永久性视力丧失，尤其是在慢性病例中。近年来，已对采用标准和低剂量/低能量方案的维替泊芬光动力疗法、抗血管内皮生长因子、糖皮质激素拮抗剂、盐皮质激素受体拮抗剂以及参数各异的阈下微脉冲激光作为治疗选择进行了研究。在本综述中，我们评估了2000年以后开展的随机和非随机病例系列研究，这些研究纳入了至少3例病程超过3个月的慢性CSCR患者，他们接受了目前针对慢性CSCR的治疗方案。
